292 related articles for article (PubMed ID: 2314822)
21. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Gynecol Obstet Invest; 1989; 27(2):102-4. PubMed ID: 2731767
[TBL] [Abstract][Full Text] [Related]
22. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Wils J; van Geuns H
Am J Clin Oncol; 1989 Jun; 12(3):251-4. PubMed ID: 2658540
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
25. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
26. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
27. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
[TBL] [Abstract][Full Text] [Related]
28. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
30. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
32. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
33. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
34. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer.
Luesley D; Lawton F; Blackledge G; Hilton C; Kelly K; Rollason T; Wade-Evans T; Jordan J; Fielding J; Latief T
Lancet; 1988 Sep; 2(8611):599-603. PubMed ID: 2900980
[TBL] [Abstract][Full Text] [Related]
35. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
[TBL] [Abstract][Full Text] [Related]
36. Place of second-look laparotomy after 18 courses of chemotherapy in epithelial ovarian cancer.
Ngan HY; Wong LC; Ma HK
Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):52-4. PubMed ID: 2562603
[TBL] [Abstract][Full Text] [Related]
37. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients.
de Gramont A; Drolet Y; Varette C; Louvet C; Gonzalez-Canall G; Krulik M; Cady J; Pigne A; Marpeau L; Barrat J
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):451-7. PubMed ID: 2702999
[TBL] [Abstract][Full Text] [Related]
38. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1995; 16(1):12-7. PubMed ID: 7744111
[TBL] [Abstract][Full Text] [Related]
39. A review of second-look laparotomy for ovarian cancer.
Cain JM; Saigo PE; Pierce VK; Clark DG; Jones WB; Smith DH; Hakes TB; Ochoa M; Lewis JL
Gynecol Oncol; 1986 Jan; 23(1):14-25. PubMed ID: 3943748
[TBL] [Abstract][Full Text] [Related]
40. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]